Navigation Links
New recommendations issued for use of cetuximab in colon cancer therapy
Date:7/16/2010

Chapel Hill, NC In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

Based on earlier studies, cetuximab is now indicated for treatment of patients with advanced colorectal cancer whose tumors do not have a mutation in the KRAS gene. KRAS is one of a series of genes along a pathway that can lead tumors cells to grow, divide and evade signals that shut the cells down causing their death. Based on the results in advanced disease, researchers had hoped to see similar benefits when cetuximab was added to a standard chemotherapy regimen in earlier stages of colon cancer. However, ongoing analysis during the clinical trial found that patients receiving the combination therapy had no significant improvement in survival compared to standard therapy.

Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) a cell signaling pathway that contributes to tumor growth. The drug is given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer. Previously, researchers found that patients with a mutated KRAS gene about 40 percent of those with metastatic colon cancer do not respond to the EGFR inhibitors currently in use.

However, the genetic test for KRAS mutation was not standard until this trial was well underway. Patients enrolled before KRAS testing were segmented from those in the rest of the study and analyzed separately, said Richard Goldberg, MD, chief of the division of hematology/oncology at the UNC-Chapel Hill School of Medicine, who presented the results for this group of patients.

"We expected that patients with the genetic mutation would not respond to cetuximab, and that is what we found," said Goldberg, who is also physician-in-chief of the N.C. Cancer Hospital.

"However, even the patients in the study whose tumors did not harbor the KRAS mutation did not benefit significantly from the combination therapy and the standard treatment proved to have the best results. We also found that the combination therapy was more toxic and the side effects of treatment especially in older patients negatively impacted their ability to complete the standard treatment," he added.

The researchers issued a recommendation that cetuximab should not be used in patients with stage III colon cancer. It remains a valuable tool in treating patients with advanced colorectal cancers whose tumors do not harbor a KRAS mutation and can either be administered as a single agent or with chemotherapy.


'/>"/>

Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. AGA offers new recommendations for CRC surveillance for certain patients with IBD
2. ACR, SBI: Avon Survey Reveals Potentially Deadly Effects of USPSTF Mammography Recommendations
3. Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism
4. Critical recommendations unveiled: Deep-vein thrombosis and pulmonary embolism
5. Critical Recommendations Unveiled to Respond to National Public Health Crisis: Deep-Vein Thrombosis and Pulmonary Embolism
6. SIUE Pain Summit Recommendations Announced Today
7. G8 to receive recommendations on women and childrens health
8. ACR task force makes recommendations for improving relationships between radiologists and hospitals
9. Aspirin recommendations changed for many younger diabetic patients
10. Study finds poor compliance with cirrhosis surveillance recommendations
11. New Guidelines Issued on Hormone Receptor Testing for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi ... be included in the 2016 “Guide to America’s Top Plastic Surgeons” for seven ... amalgamation of their education, experience, and professional associations. , One the most ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud ... Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are ... are prolonging life 6 years in the last 3 decades,” says Dr. Valentine ...
(Date:12/2/2016)... ... December 02, 2016 , ... The ... Waikiki Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity ... management. , The demand for supplemental training related to pain management has ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... plc (NYSE: AGN ), a leading global pharmaceutical ... Share Repurchase (ASR) Program. Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO ... , , ... Company entered into a variable tenor ASR arrangement on  November ... of its ordinary shares. Approximately 40.5 million shares worth $8 ...
(Date:11/30/2016)... -- Research and Markets has announced the ... Neurosurgical and Monitoring Devices 2017 - MedView" report to ... , ... report suite on the U.S. market for neurological devices includes ... monitoring devices, detachable coils, liquid embolics, catheters, guidewires, balloon occlusion ...
(Date:11/30/2016)... Varian Medical Systems (NYSE: VAR ... Company in the Healthcare Equipment and Services industry, according ... "JUST 100 List." The rankings are based on criteria ... on attitudes towards corporate behavior, involving 50,000 Americans over ... companies against their peers within 32 major industries. The ...
Breaking Medicine Technology: